Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 4/6 |
Rewards
Risk Analysis
+ 1 more risk
Narratives
BetaNarratives bring a range of perspectives from our community.
Warren
Based on Analyst Price Targets
Price at publication US$129.45
Updated
Merck & Co., Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$121.44 |
52 Week High | US$130.24 |
52 Week Low | US$99.14 |
Beta | 0.38 |
1 Month Change | -4.97% |
3 Month Change | 14.04% |
1 Year Change | 14.73% |
3 Year Change | 56.68% |
5 Year Change | 47.47% |
Change since IPO | 10,694.67% |
Recent News & Updates
Recent updates
Merck: A High-Conviction Investment For Long-Term Growth
Feb 29Merck: Big Pharma Looks Stronger Than Ever Ahead Of 2023 Earnings
Jan 29Is Merck & Co., Inc. (NYSE:MRK) Trading At A 47% Discount?
Jan 26Merck's Soaring Stock: Examining The Euphoria Amidst Potential Pitfalls
Jan 08Merck: One Of The Best - Unveiling The Trifecta Of Safety, Dividends, And Growth
Dec 25Merck (NYSE:MRK) Is Increasing Its Dividend To $0.77
Dec 08Shareholder Returns
MRK | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.1% | -0.3% | 0.5% |
1Y | 14.7% | 22.4% | 29.0% |
Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned 22.4% over the past year.
Return vs Market: MRK underperformed the US Market which returned 29% over the past year.
Price Volatility
MRK volatility | |
---|---|
MRK Average Weekly Movement | 2.3% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1891 | 71,000 | Rob Davis | https://www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
MRK fundamental statistics | |
---|---|
Market cap | US$307.56b |
Earnings (TTM) | US$365.00m |
Revenue (TTM) | US$60.12b |
842.6x
P/E Ratio5.1x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MRK income statement (TTM) | |
---|---|
Revenue | US$60.12b |
Cost of Revenue | US$15.92b |
Gross Profit | US$44.20b |
Other Expenses | US$43.84b |
Earnings | US$365.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
Earnings per share (EPS) | 0.14 |
Gross Margin | 73.53% |
Net Profit Margin | 0.61% |
Debt/Equity Ratio | 93.1% |
How did MRK perform over the long term?
See historical performance and comparison